title: Systemically administered liposome-encapsulated Ad-PEDF potentiates the anti-cancer effects in mouse lung metastasis melanoma.
abstract: BACKGROUND
  The use of adenoviral vector for gene therapy is still an important strategy for advanced cancers, however, the lack of the requisite coxsackie-adenovirus receptor in cancer cells and host immune response to adenovirus limit the application of adenoviral vector in vivo.
  
  
  METHODS
  We designed the antiangiogenic gene therapy with recombinant PEDF adenovirus (Ad-PEDF) encapsulated in cationic liposome (Ad-PEDF/Liposome), and investigated the anti-tumor efficacy of Ad-PEDF/Liposome complex on inhibition of tumor metastasis.
  
  
  RESULTS
  We found that systemic administration of Ad-PEDF/liposome was well tolerated and resulted in marked suppression of tumor growth, and was more potent than uncoated Ad-PEDF to induce apoptosis in B16-F10 melanoma cells and inhibit murine pulmonary metastases in vivo. After Ad-luciferase was encapsulated with liposome, its distribution decreased in liver and increased in lung. The anti-Ad IgG level of Ad-PEDF/Liposome was significantly lower than Ad-PEDF used alone.
  
  
  CONCLUSIONS
  The present findings provide evidences of systematic administration of cationic liposome-encapsulated Ad-PEDF in pulmonary metastatic melanoma mice model, and show an encouraging therapeutic effect for further exploration and application of more complexes based on liposome-encapsulated adenovirus for more cancers.
authors.affiliation: State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Clinical Medicine School, Sichuan University, Chengdu, Sichuan, PR China.
authors.forename: Hua-shan
authors.initials: HS
authors.lastname: Shi
authors.forename: Li-ping
authors.initials: LP
authors.lastname: Yang
authors.forename: Wei
authors.initials: W
authors.lastname: Wei
authors.forename: Xiao-qing
authors.initials: XQ
authors.lastname: Su
authors.forename: Xiao-peng
authors.initials: XP
authors.lastname: Li
authors.forename: Meng
authors.initials: M
authors.lastname: Li
authors.forename: Shun-tao
authors.initials: ST
authors.lastname: Luo
authors.forename: Hai-long
authors.initials: HL
authors.lastname: Zhang
authors.forename: Lian
authors.initials: L
authors.lastname: Lu
authors.forename: Yong-qiu
authors.initials: YQ
authors.lastname: Mao
authors.forename: Bing
authors.initials: B
authors.lastname: Kan
authors.forename: Li
authors.initials: L
authors.lastname: Yang
mesh_terms: D000256:Adenoviridae / Q000235:genetics*; D000818:Animals; D002412:Cations; D005136:Eye Proteins / Q000235:genetics*; D005260:Female; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors; D007074:Immunoglobulin G / Q000737:chemistry; D008081:Liposomes / Q000737:chemistry / Q000378:metabolism*; D008175:Lung Neoplasms / Q000473:pathology* / Q000628:therapy*; D008545:Melanoma / Q000473:pathology* / Q000628:therapy*; D008546:Melanoma, Experimental; D051379:Mice; D008810:Mice, Inbred C57BL; D009362:Neoplasm Metastasis; D009414:Nerve Growth Factors / Q000235:genetics*; D015843:Serpins / Q000235:genetics*; D000099174:Pigment Epithelium-Derived Factor
chemical_list: D002412:Cations; D005136:Eye Proteins; D007074:Immunoglobulin G; D008081:Liposomes; D009414:Nerve Growth Factors; D015843:Serpins; D000099174:Pigment Epithelium-Derived Factor
references.citation: Jpn J Cancer Res. 2000 Apr;91(4):363-7
references.pmid: 10804282
references.citation: Semin Oncol. 2007 Dec;34(6):555-65
references.pmid: 18083379
references.citation: Proc Natl Acad Sci U S A. 1987 Nov;84(21):7413-7
references.pmid: 2823261
references.citation: Gene Ther. 1995 Oct;2(8):521-30
references.pmid: 8593602
references.citation: Gene Ther. 2002 Feb;9(3):176-82
references.pmid: 11859420
references.citation: Exp Mol Med. 2008 Aug 31;40(4):427-34
references.pmid: 18779655
references.citation: Invest Ophthalmol Vis Sci. 1989 Aug;30(8):1700-7
references.pmid: 2668219
references.citation: Nat Med. 1995 Jan;1(1):27-31
references.pmid: 7584949
references.citation: Hum Gene Ther. 1998 Nov 1;9(16):2363-73
references.pmid: 9829535
references.citation: Biophys J. 1996 Aug;71(2):590-9
references.pmid: 8842198
references.citation: Cancer Gene Ther. 2000 Oct;7(10):1329-35
references.pmid: 11059690
references.citation: Hum Gene Ther. 1998 Nov 20;9(17):2493-502
references.pmid: 9853516
references.citation: Nature. 2011 Mar 24;471(7339):518-22
references.pmid: 21430780
references.citation: Cancer Res. 2001 Apr 1;61(7):2953-60
references.pmid: 11306473
references.citation: Science. 1999 Jul 9;285(5425):245-8
references.pmid: 10398599
references.citation: Cancer Res. 2007 Jun 15;67(12):5940-8
references.pmid: 17575164
references.citation: Hum Gene Ther. 1997 Jul 1;8(10):1195-206
references.pmid: 9215737
references.citation: Nat Genet. 1994 Sep;8(1):42-51
references.pmid: 7527271
references.citation: Hum Gene Ther. 2002 Jan 1;13(1):143-54
references.pmid: 11779418
references.citation: Int J Oncol. 2002 Dec;21(6):1161-74
references.pmid: 12429964
references.citation: Dermatoendocrinol. 2009 Mar;1(2):108-13
references.pmid: 20224693
references.citation: Gene Ther. 2004 Dec;11(23):1694-702
references.pmid: 15496964
references.citation: Am J Pathol. 2004 Apr;164(4):1225-32
references.pmid: 15039211
references.citation: Oncogene. 2009 Nov 26;28(47):4147-61
references.pmid: 19767774
references.citation: ChemMedChem. 2007 Mar;2(3):292-6
references.pmid: 17191293
references.citation: Curr Pharm Des. 2008;14(36):3802-9
references.pmid: 19128233
references.citation: J Natl Cancer Inst. 2005 Feb 2;97(3):172-87
references.pmid: 15687360
references.citation: J Exp Clin Cancer Res. 2009 Jun 05;28:75
references.pmid: 19500366
references.citation: Science. 1997 Feb 28;275(5304):1320-3
references.pmid: 9036860
references.citation: Clin Cancer Res. 2010 Dec 1;16(23):5862-72
references.pmid: 21030496
references.citation: Exp Cell Res. 1999 Oct 10;252(1):1-12
references.pmid: 10502394
references.citation: Atherosclerosis. 1996 Jul;124(1):49-60
references.pmid: 8800493
references.citation: J Biol Chem. 1992 Jun 5;267(16):10931-4
references.pmid: 1375931
references.citation: Adv Exp Med Biol. 1998;451:335-43
references.pmid: 10026893
references.citation: Clin Cancer Res. 2005 Oct 15;11(20):7444-53
references.pmid: 16243818
references.citation: J Virol Methods. 2005 Jun;126(1-2):31-6
references.pmid: 15847916
references.citation: Invest Ophthalmol Vis Sci. 2010 Jan;51(1):28-34
references.pmid: 19661223
references.citation: Gene Ther. 2008 Feb;15(4):247-56
references.pmid: 18097470
references.citation: Cancer Res. 1999 Oct 1;59(19):4770-5
references.pmid: 10519381
references.citation: N Engl J Med. 1971 Nov 18;285(21):1182-6
references.pmid: 4938153
references.citation: CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96
references.pmid: 18287387
references.citation: Gene Ther. 1998 Jul;5(7):995-1002
references.pmid: 9813671
references.citation: Cancer Gene Ther. 2010 Jan;17(1):49-57
references.pmid: 19609295
references.citation: Anticancer Res. 2000 May-Jun;20(3A):1653-6
references.pmid: 10928086
references.citation: Cancer Gene Ther. 2010 Jan;17(1):28-36
references.pmid: 19498459
references.citation: Exp Cell Res. 2006 May 15;312(9):1566-80
references.pmid: 16542650
references.citation: Cancer Res. 2007 Nov 15;67(22):10849-58
references.pmid: 18006830
references.citation: Am J Physiol Cell Physiol. 2002 May;282(5):C947-70
references.pmid: 11940508
references.citation: Mol Ther. 2002 Mar;5(3):233-41
references.pmid: 11863412
references.citation: Blood. 2004 Sep 15;104(6):1631-8
references.pmid: 15161670
references.citation: Hum Gene Ther. 1998 Mar 1;9(4):507-20
references.pmid: 9525312